Alzheimer’s Disease Therapeutics Market to Gain Traction Amidst Covid-19 Crisis

The outbreak of Covid-19 is not going that well with those suffering from Alzheimer’s disease. Due to memory loss, adhering to a routine is imperative. However, the ongoing pandemic has disturbed the routine of almost everyone. Alzheimer’s-infected people do have a devastating experience, as their routine, in the normal course, needs to be catered to by caretaker (s). With Covid-19 on the table, Both – the caretaker and patient need to be doubly careful as both are at equal risk of contracting Covid-19. These factors are expected to accelerate have been accelerating the Alzheimer’s disease therapeutics market since Mar 2020 as healthcare personnel are trying their best to keep Alzheimer’s under check, so that protection against Covid-19 could be looked into.

On the other hand, the influx of innovation is there to keep the cash registers ringing. For example, new-fangled cloud-based cognitive assessment systems are being developed, which help in catching the drugs in patients. As such, pharmaceutical companies are able to evaluate safety and efficacy of the drugs in pipeline for treating the disease. This advancement in diagnostic technologies is expected to push the growth of Alzheimer’s disease therapeutics market.

How much more depth to fathom herein?

CANTAB Connect is another technology. It is developed by Cambridge Cognition for observing efficacy of treatment in moderate and mild cases of Alzheimer’s disease, especially at the time of clinical trials.

Drugs like LMTX developed by TauRx Pharmaceuticals Ltd. are also looked upon as an effective means to treat this neurodegenerative, non-reversible disorder. The geriatric population is also exploding all over. Research states that Alzheimer’s usually happens to those who are aged 65 and above.

Also, post introduction of Alzheimer’s Combination Therapy Opportunities in collaboration with Alzheimer’s Society UK, Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, repurposed or repositioned drugs have hit the market.

What do geographies have to say?

North America held the largest market share in the year 2019 due to proper healthcare infrastructure and facilities in the US. The patients’ buying power regarding expensive drugs also adds to the growth. Europe comes in second on the similar grounds. The Asia-Pacific is expected to grow at the fastest pace due to people taking Alzheimer’s disease seriously in terms of treatment.

On the whole, Alzheimer’s disease therapeutics market has grown twofold since Mar 2020 and is expected to continue post-Covid-19 era as well, as prevention would be preferred than cure.